Trial
NCT03222622
Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Betta Pharmaceuticals Co., Ltd.
Collaborators
Tigermed Consulting Co., Ltd
Condition
Mild to Moderate Psoriasis
Intervention
Icotinib hydrochloride cream
Why stopped
The efficacy failed to meet the primary efficacy endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-14